Bronchoscopic lung volume reduction in emphysema: a review.
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
medline:
6
12
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
ppublish
Résumé
Chronic obstructive pulmonary disease (COPD) poses a substantial burden on the healthcare system and is currently considered the sixth leading cause of death in the United States. Emphysema, as evidenced by severe air-trapping in patients with COPD, leads to significant dyspnea and morbidity. Lung volume reduction via surgery or minimally invasive endobronchial interventions are currently available, which improve lung function and quality of life. Newer studies have noted a survival benefit in patients post bronchoscopic lung volume reduction vs. those subjected to standard of care. The presence of collateral ventilation is one of the most common impeding factors to placing endobronchial valves, and if placed, these patients might not achieve lobar atelectasis; however, there are newer modalities that are now available for patients with collateral ventilation which we have described. Combining standard of care treatment that includes smoking cessation, bronchodilators, preventive care including vaccinations, pulmonary rehabilitation, and endobronchial treatment using various interventions in decreasing hyperinflation improves quality of life and may improve survival and hence significantly reduce the burden of COPD on healthcare.
Identifiants
pubmed: 37916600
doi: 10.1097/MCP.0000000000001031
pii: 00063198-990000000-00121
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-67Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Chronic obstructive pulmonary disease (COPD). Available at: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd ) [Accessed 12 July 2023].
Syamlal G, Kurth LM, Dodd KE, et al. Chronic obstructive pulmonary disease mortality by industry and occupation – United States, 2020. MMWR Morb Mortal Wkly Rep 2022; 71:1550–1554.
Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease. 2023. Report: GOLD executive summary. Am J Respir Crit Care Med; 2023;207:819–37.
Criner GJ, Cordova F, Sternberg AL, et al. The National Emphysema Treatment Trial (NETT). Part II. Lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med 2011; 184:881–893.
Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059–2073.
Naunheim KS, Wood DE, Mohsenifar Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006; 82:431–443.
Gompelmann D, Benjamin N, Bischoff E, et al. Survival after endoscopic valve therapy in patients with severe emphysema. Respiration 2019; 97:145–152.
Hartman JE, Welling JBA, Klooster K, et al. Survival in COPD patients treated with bronchoscopic lung volume reduction. Respir Med 2022; 196:106825.
Garner JL, Kemp SV, Srikanthan K, et al. 5-Year survival after endobronchial coil implantation: secondary analysis of the first randomised controlled trial, RESET. Respiration 2020; 99:154–162.
Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000; 16:269–275.
O’Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997; 155:109–115.
Zulueta JJ, Wisnivesky JP, Henschke CI, et al. Emphysema scores predict death from COPD and lung cancer. Chest 2012; 141:1216–1223.
Haruna A, Muro S, Nakano Y, et al. CT scan findings of emphysema predict mortality in COPD. Chest 2010; 138:635–640.
Ash SY, San José Estépar R, Fain SB, et al. Relationship between emphysema progression at CT and mortality in ever-smokers: results from the COPDGene and ECLIPSE cohorts. Radiology 2021; 299:222–231.
Kim Y, Kim SH, Rhee CK, et al. Air trapping and the risk of COPD exacerbation: analysis from prospective KOCOSS Cohort. Front Med (Lausanne) 2022; 9:835069.
Sciurba FC, Ernst A, Herth FJF, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010; 363:1233–1244.
Herth FJF, Noppen M, Valipour A, et al. Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. Eur Respir J 2012; 39:1334–1342.
Gompelmann D, Eberhardt R, Slebos D-J, et al. Study of the use of Chartis® pulmonary assessment system to optimize subject selection for endobronchial lung volume reduction (ELVR) – results and subgroup analysis. Chest 2011; 140:546A.
Herth FJF, Eberhardt R, Gompelmann D, et al. Radiological and clinical outcomes of using Chartis TM to plan endobronchial valve treatment. Eur Respir J 2013; 41:302–308.
Koster TD, van Rikxoort EM, Huebner R-H, et al. Predicting lung volume reduction after endobronchial valve therapy is maximized using a combination of diagnostic tools. Respiration 2016; 92:150–157.
Klooster K, Koster TD, Ruwwe-Glösenkamp C, et al. An integrative approach of the fissure completeness score and Chartis assessment in endobronchial valve treatment for emphysema. Int J Chron Obstruct Pulmon Dis 2020; 15:1325–1334.
Labarca G, Uribe JP, Pacheco C, et al. Bronchoscopic lung volume reduction with endobronchial zephyr valves for severe emphysema: a systematic review and meta-analysis. Respiration 2019; 98:268–278.
Wienker J, Karpf-Wissel R, Funke F, et al. Predictive value of Chartis measurement for lung function improvements in bronchoscopic lung volume reduction. Ther Adv Respir Dis 2020; 14:1753466620932507.
Criner GJ, Sue R, Wright S, et al. A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med 2018; 198:1151–1164.
Li S, Wang G, Wang C, et al. The REACH Trial: a randomized controlled trial assessing the safety and effectiveness of the Spiration® valve system in the treatment of severe emphysema. Respiration 2019; 97:416–427.
Valipour A, Slebos D-J, Herth F, et al. Endobronchial valve therapy in patients with homogeneous emphysema. results from the IMPACT study. Am J Respir Crit Care Med 2016; 194:1073–1082.
Klooster K, ten Hacken NHT, Hartman JE, et al. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med 2015; 373:2325–2335.
Darwiche K, Karpf-Wissel R, Eisenmann S, et al. Bronchoscopic lung volume reduction with endobronchial valves in Low-FEV1 patients. Respiration 2016; 92:414–419.
Trudzinski FC, Höink AJ, Leppert D, et al. Endoscopic lung volume reduction using endobronchial valves in patients with severe emphysema and very low FEV1. Respiration 2016; 92:258–265.
van Dijk M, Hartman JE, Klooster K, et al. Endobronchial valve treatment in emphysema patients with a very low DLCO. Respiration 2020; 99:163–170.
Eberhardt R, Gerovasili V, Kontogianni K, et al. Endoscopic lung volume reduction with endobronchial valves in patients with severe emphysema and established pulmonary hypertension. Respiration 2014; 89:41–48.
van der Molen MC, Hartman JE, Vanfleteren LEGW, et al. Reduction of lung hyperinflation improves cardiac preload, contractility, and output in emphysema: a clinical trial in patients who received endobronchial valves. Am J Respir Crit Care Med 2022; 206:704–711.
Shah PL, Zoumot Z, Singh S, et al. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. Lancet Respir Med 2013; 1:233–240.
Deslee G, Klooster K, Hetzel M, et al. Lung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial. Thorax 2014; 69:980–986.
Sciurba FC, Criner GJ, Strange C, et al. Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema: the RENEW Randomized Clinical Trial. JAMA 2016; 315:2178–2189.
Klooster K, Valipour A, Marquette C-H, et al. Endobronchial coil system versus standard-of-care medical management in the treatment of subjects with severe emphysema. Respiration 2021; 100:804–810.
Majid A, Labarca G, Uribe JP, et al. Efficacy of the spiration valve system in patients with severe heterogeneous emphysema: a systematic review and meta-analysis. Respiration 2020; 99:62–72.
Iftikhar IH, Schimmel M, Sardi A, et al. Bronchoscopic lung volume reduction with valves and coils. A network meta-analysis. Ann Am Thorac Soc 2020; 17:1468–1475.
Patel M, Chowdhury J, Zhao H, et al. Meta-analysis and systematic review of bronchoscopic lung volume reduction through endobronchial valves in severe emphysema. J Bronchology Interv Pulmonol 2022; 29:224–237.
Perch M, Riise GC, Hogarth K, et al. Endoscopic treatment of native lung hyperinflation using endobronchial valves in single-lung transplant patients: a multinational experience. Clin Respir J 2015; 9:104–110.
Delage A, Hogarth DK, Zgoda M, et al. Endobronchial valve treatment in patients with severe emphysema due to alpha-1 antitrypsin deficiency. Eur Respir J 2019; 54: doi:10.1183/13993003.congress-2019.PA4800.
doi: 10.1183/13993003.congress-2019.PA4800
Tuohy MM, Remund KF, Hilfiker R, et al. Endobronchial valve deployment in severe α-1 antitrypsin deficiency emphysema: a case series. Clin Respir J 2013; 7:45–52.
Hillerdal G, Mindus S. One- to four-year follow-up of endobronchial lung volume reduction in alpha-1-antitrypsin deficiency patients: a case series. Respiration 2014; 88:320–328.
Everaerts S, Hartman JE, Van Dijk M, et al. bronchoscopic lung volume reduction in patients with emphysema due to alpha-1 antitrypsin deficiency. Respiration 2023; 102:134–142.
Wagh A, Ravikumar N, Hogarth DK. Pneumothorax as a result of bronchoscopic lung volume reduction with endobronchial valves: a clinical practice review of risk and management strategies. Shanghai Chest 2023; 7: doi:10.21037/shc-22-34.
doi: 10.21037/shc-22-34
Gompelmann D, Lim H-J, Eberhardt R, et al. Predictors of pneumothorax following endoscopic valve therapy in patients with severe emphysema. Int J Chron Obstruct Pulmon Dis 2016; 11:1767–1773.
Slebos D-J, Shah PL, Herth FJF, et al. Endobronchial valves for endoscopic lung volume reduction: best practice recommendations from expert panel on endoscopic lung volume reduction. Respiration 2017; 93:138–150.
Valipour A, Slebos D-J, de Oliveira HG, et al. Expert statement: pneumothorax associated with endoscopic valve therapy for emphysema—potential mechanisms, treatment algorithm, and case examples. Respiration 2014; 87:513–521.
van Dijk M, Sue R, Criner GJ, et al. Expert statement: pneumothorax associated with one-way valve therapy for emphysema: 2020 update. Respiration 2021; 100:969–978.
Mahajan A ‘Bobby’, Bari M, Collar N, et al. Safety of home discharge with a chest tube after bronchoscopic lung volume reduction complicated by persistent airleak. J Bronchol Interv Pulm . Epub ahead of print 13 September 2023. doi:10.1097/LBR.0000000000000945.
Roodenburg SA, Hartman JE, Deslée G, et al. Bronchoscopic lung volume reduction coil treatment for severe emphysema: a systematic review and meta-analysis of individual participant data. Respiration 2022; 101:697–705.
Herth FJF, Valipour A, Shah PL, et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med 2016; 4:185–193.
Garner J, Kemp SV, Toma TP, et al. Survival after endobronchial valve placement for emphysema: a 10-year follow-up study. Am J Respir Crit Care Med 2016; 194:519–521.
Hopkinson NS, Kemp SV, Toma TP, et al. Atelectasis and survival after bronchoscopic lung volume reduction for COPD. Eur Respir J 2011; 37:1346–1351.
Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005–1012.
Klooster K, Hartman JE, ten Hacken NHT, et al. Improved predictors of survival after endobronchial valve treatment in patients with severe emphysema. Am J Respir Crit Care Med 2017; 195:1272–1274.
Buttery SC, Banya W, Bilancia R, et al. Lung volume reduction surgery versus endobronchial valves: a randomised controlled trial. Eur Respir J 2023; 61:2202063.
Kramer MR, Refaely Y, Maimon N, et al. Bilateral endoscopic sealant lung volume reduction therapy for advanced emphysema. Chest 2012; 142:1111–1117.
Herth FJF, Gompelmann D, Stanzel F, et al. Treatment of advanced emphysema with emphysematous lung sealant (AeriSeal®). Respiration 2011; 82:36–45.
Come CE, Kramer MR, Dransfield MT, et al. A randomised trial of lung sealant versus medical therapy for advanced emphysema. Eur Respir J 2015; 46:651–662.
Davey C, Zoumot Z, Jordan S, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet 2015; 386:1066–1073.
Kemp SV, Slebos D-J, Kirk A, et al. A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med 2017; 196:1535–1543.
Criner GJ, Delage A, Voelker K, et al. Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial. Am J Respir Crit Care Med 2019; 200:1354–1362.